Intratumoral administration of the drug SAR441000 (a mix of four mRNAs encoding IL-12, single-chain IFN-α-2b, GM-CSF, and the IL-15 sushi domain) alone or in combination with cemiplimab demonstrated anti-tumor activity in locoregional lesions, while no significant effects were observed in patients with advanced solid tumors previously treated with ICI therapy. Here, IFNA2 is linked to neoplasm.